Fund moves

Boston Scientific (BSX): AIA Group Ltd reduced its stake -8,790 shares

AIA Group Ltd reduced its stake in Boston Scientific, per its Q3 2025 13F.

105K
Shares reported · -8,790 vs prior quarter
0.18%
Disclosed portfolio weight
$10.3M
Reported value
Holdings as of
Sep 30, 2025
Filed
Dec 18, 2025

What stands out in this filing

  • 114,255 shares in Q2 2025, 105,465 now (−7.7% in share count).
  • Reported at $10.3M, 0.18% of the portfolio value in this 13F filing.
  • 64 other tracked managers reported the same kind of change for Q3 2025.

Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Oct 17, 2025CongressDisclosed purchase of BSX — reported range $1,001 - $15,000
  2. Oct 22, 2025Company filing · Form 8-K · ResultsReported its results
  3. Oct 22, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On October 22, 2025, John E. Sununu informed Boston Scientific Corporation (the “Company”) that he will not stand for re-election at the Company’s 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”).”
  4. Oct 27, 2025InsiderDirector sold ~$1.01M of BSX shares in the open market
  5. Oct 28, 2025InsiderDirector sold ~$297K of BSX shares in the open market
  6. Oct 28, 2025CongressDisclosed partial sale of BSX — reported range $15,001 - $50,000
  7. Oct 30, 2025Congress · 1 personMembers of Congress: 1 purchase, 1 sale
  8. Oct 31, 2025CongressDisclosed sale of BSX — reported range $1,001 - $15,000
  9. Nov 3, 2025Insider · 1 personInsiders: 3 sales (~$5.0M)
  10. Nov 6, 2025InsiderDirector sold ~$1.27M of BSX shares in the open market
  11. Nov 18, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On November 18, 2025, upon the recommendation of the Executive Compensation and Human Resources Committee (the “Compensation Committee”), the Board of Directors (the “Board”) of Boston Scientific Corporation (the “Company”) approved the Company’s 2026 Annual Bonus Plan effective for the performance year of January 1, 2026 through December 31, 2026 (the “2026 Annual Bonus Plan”).”
  12. Nov 18, 2025CongressDisclosed purchase of BSX — reported range $1,001 - $15,000
  13. Dec 1, 2025InsiderOfficer sold ~$1.76M of BSX shares in the open market
  14. Dec 16, 2025Federal contract · $519K obligatedDepartment of Veterans Affairs awarded Boston Scientific: $519K obligated to date
  15. Dec 17, 2025CongressDisclosed partial sale of BSX — reported range $1,001 - $15,000

What came next

  1. Dec 19, 2025FDARecall: HOT AXIOS Stent and Electrocautery-Enhanced Delivery System 6mm x 8mm; Material Number (UPN): M00553520;
  2. Dec 19, 2025FDARecall: AXIOS Stent and Electrocautery-Enhanced Delivery System - 20mm x 10mm; Material Number (UPN): M00553660;
  3. Dec 19, 2025FDARecall: *HOT AXIOS Stent and Electrocautery-Enhanced Delivery System 20mm x 10mm; Material Number (UPN): M00553560;
  4. Dec 19, 2025FDARecall: AXIOS Stent and Electrocautery-Enhanced Delivery System - 6mm x 8mm; Material Number (UPN): M00553680;
  5. Dec 24, 2025CongressDisclosed partial sale of BSX — reported range $1,001 - $15,000
  6. Dec 29, 2025CongressDisclosed purchase of BSX — reported range $15,001 - $50,000
  7. Jan 14, 2026Company filing · Form 8-K · Material agreementSigned an important agreement
  8. Jan 23, 2026FDAFDA device clearance: BodyGuardian Remote Monitoring System (BGRMS v3.0)
  9. Jan 30, 2026CongressDisclosed purchase of BSX — reported range $1,001 - $15,000
  10. Feb 2, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On February 2, 2026, Yoshiaki Fujimori informed Boston Scientific Corporation (the “Company”) that he will not stand for re-election at the Company’s 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”).”
  11. Feb 2, 2026Insider · 1 personInsiders: 2 sales (~$15.0M)
  12. Feb 4, 2026Company filing · Form 8-K · ResultsReported its results
  13. Feb 10, 2026FDAFDA device clearance: SpaceOAR Vue System (SV-2101)
  14. Feb 10, 2026FDARecall: EndoVive Safety PEG Kit; Outer Box Material Number (UPN): M00509001; Inner Box Material Number (UPN): M00509000;
  15. Feb 10, 2026CongressDisclosed purchase of BSX — reported range $1,001 - $15,000
  16. Feb 12, 2026Federal contract · $519K obligatedDepartment of Veterans Affairs awarded Boston Scientific: $519K obligated to date
  17. Feb 18, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors (and 1 more item)“On February 18, 2026 the Board of Directors (the “ Board ”) of Boston Scientific Corporation (the “ Company ”), upon the recommendation of the Nominating and Governance Committee of the Board, increased the number of directors comprising the Board from ten to twelve, and appointed each of Catherine R. Smith and Christophe P. Weber to be a director of the Company, to hold office until the next annual meeting of…”
  18. Feb 26, 2026Company filing · Form 8-K · Material agreement, Agreement endedSigned an important agreement, and ended an important agreement (and 1 more item)
  19. Mar 5, 2026Court · District Court, D. MassachusettsSecurities lawsuit filed: In re: Boston Scientific Corporation Securities Litigation
  20. Mar 5, 2026Court · District Court, D. MassachusettsSecurities lawsuit filed: Troike v. Boston Scientific Corporation
View the official recordSEC Form 13F-HR

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Boston Scientific

For Boston Scientific, OQRO holds 1 insider filing (SEC Form 4 or Form 144), 7 Congress trade reports, 2 fund holdings reports (13F) and 5 federal contract awards dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its BSX page.

How this filing works

Explore the data

Common questions

What does this filing report about Boston Scientific (BSX) stock?

AIA Group Ltd reduced its stake in Boston Scientific, per its Q3 2025 13F. Now 105K shares, $10.3M reported value, 0.18% of disclosed portfolio.

When did it happen, and when was it made public?

Holdings as of: Sep 30, 2025. Filed: Dec 18, 2025.

What stands out in this filing?

114,255 shares in Q2 2025, 105,465 now (−7.7% in share count). Reported at $10.3M, 0.18% of the portfolio value in this 13F filing. 64 other tracked managers reported the same kind of change for Q3 2025.

Is this a trade made on a known date?

No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.

Where does this information come from?

From the SEC Form 13F-HR, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Boston Scientific recently?

For Boston Scientific, OQRO holds 1 insider filing (SEC Form 4 or Form 144), 7 Congress trade reports, 2 fund holdings reports (13F) and 5 federal contract awards dated in the last 90 days. They are listed on the BSX page.

Does this mean BSX stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Boston Scientific

Everything OQRO holds on this company is on its BSX page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data